PL373992A1 - Sposób hodowli komórek podstawowych i amplifikacji wirusów w warunkach braku surowicy - Google Patents

Sposób hodowli komórek podstawowych i amplifikacji wirusów w warunkach braku surowicy

Info

Publication number: PL373992A1
Authority: PL; Poland
Prior art keywords: primary cells; serum free; cultivation; amplification; free conditions
Prior art date: 2002-09-05

Application number

PL03373992A

Other languages

English (en)

Other versions

PL215169B1 (pl

Inventor

Ingmar Räthe

Eva Felder

Karl Heller

Original Assignee

Bavarian Nordic A/S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-05

Filing date

2003-09-01

Publication date

2005-09-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31970216&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL373992(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-09-01 Application filed by Bavarian Nordic A/S filed Critical Bavarian Nordic A/S

2005-09-19 Publication of PL373992A1 publication Critical patent/PL373992A1/pl

2013-10-31 Publication of PL215169B1 publication Critical patent/PL215169B1/pl

Links

238000000034 method Methods 0.000 title abstract 5
241000700605 Viruses Species 0.000 title abstract 4
230000003321 amplification Effects 0.000 title abstract 2
238000003199 nucleic acid amplification method Methods 0.000 title abstract 2
210000002966 serum Anatomy 0.000 title 1
239000012679 serum free medium Substances 0.000 abstract 3
239000003102 growth factor Substances 0.000 abstract 2

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/08—Inactivation or attenuation by serial passage of virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24151—Methods of production or purification of viral material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Virology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Cell Biology (AREA)
Reproductive Health (AREA)
Gynecology & Obstetrics (AREA)
Pharmacology & Pharmacy (AREA)
Developmental Biology & Embryology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Molecular Biology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL373992A 2002-09-05 2003-09-01 Sposób amplifikacji wirusów, kompozycja zawierajaca pokswirusa uzyskanego tym sposobem oraz jego zastosowanie do otrzymywania szczepionki PL215169B1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DKPA200201302		2002-09-05

Publications (2)

Publication Number	Publication Date
PL373992A1 true PL373992A1 (pl)	2005-09-19
PL215169B1 PL215169B1 (pl)	2013-10-31

Family

ID=31970216

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL373992A PL215169B1 (pl)	2002-09-05	2003-09-01	Sposób amplifikacji wirusów, kompozycja zawierajaca pokswirusa uzyskanego tym sposobem oraz jego zastosowanie do otrzymywania szczepionki

Country Status (23)

Country	Link
US (4)	US7695939B2 (pl)
EP (1)	EP1434858B2 (pl)
JP (2)	JP2005537793A (pl)
KR (1)	KR101044538B1 (pl)
CN (1)	CN1692156B (pl)
AT (1)	ATE393212T2 (pl)
AU (1)	AU2003264144C1 (pl)
BR (1)	BRPI0313559B8 (pl)
CA (1)	CA2494379C (pl)
CY (1)	CY1114598T1 (pl)
DE (1)	DE60320520T3 (pl)
DK (1)	DK1434858T4 (pl)
EA (1)	EA009008B1 (pl)
ES (1)	ES2305514T5 (pl)
HK (1)	HK1080507B (pl)
MX (1)	MXPA04012966A (pl)
NO (1)	NO343489B1 (pl)
NZ (1)	NZ538575A (pl)
PL (1)	PL215169B1 (pl)
PT (1)	PT1434858E (pl)
SI (1)	SI1434858T2 (pl)
UA (1)	UA85543C2 (pl)
WO (1)	WO2004022729A1 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7445924B2 (en) *	2000-11-23	2008-11-04	Bavarian Nordic A/S	Modified Vaccinia Ankara virus variant and cultivation method
HU230198B1 (hu) *	2000-11-23	2015-10-28	Bavarian Nordic A/S	Módosított Vacciniavírus Ankara-variáns
AU2003264144C1 (en) *	2002-09-05	2009-12-17	Bavarian Nordic A/S	Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
EP1528101A1 (en)	2003-11-03	2005-05-04	ProBioGen AG	Immortalized avian cell lines for virus production
CN101128217B (zh)	2005-02-23	2012-04-25	巴法里安诺迪克有限公司	改良的痘病毒快速诱导抗痘病毒或其它传染物的免疫力的用途
FR2884255B1 (fr) *	2005-04-11	2010-11-05	Vivalis	Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
RU2489486C2 (ru)	2006-06-20	2013-08-10	Трансжене С.А.	Процесс получения поксвирусов и композиции поксвирусов
AU2010275764A1 (en)	2009-07-21	2012-03-15	Transgene Sa	Enzymatic composition for the digestion of chicken embryos
US20130164329A1 (en) *	2010-02-17	2013-06-27	Alnylam Pharmaceuticals, Inc.	Cell-based methods and reagents
SG184833A1 (en)	2010-04-14	2012-11-29	Emd Millipore Corp	Methods of producing high titer, high purity virus stocks and methods of use thereof
CA2802430C (en) *	2010-07-20	2021-07-20	Bavarian Nordic A/S	Method for harvesting poxvirus
KR101504159B1 (ko) *	2012-04-20	2015-03-19	한국생명공학연구원	미세조류의 성장을 촉진하는 엑소피아라 올리고스퍼마 및 이의 용도
BR112016027797A2 (pt) *	2014-06-18	2017-10-31	Medimmune Llc	métodos e meios de cultura de células compreendendo n-acetilcisteína
KR101677231B1 (ko)	2014-12-18	2016-11-30	제주대학교 산학협력단	무혈청배지（serum free medium）를 이용한 메갈로사이티바이러스의 효율적 제조방법
CN105462911B (zh) *	2015-12-22	2018-04-13	肇庆大华农生物药品有限公司	用于培养病毒的无血清培养液及其制备方法
CN107129963A (zh) *	2017-04-24	2017-09-05	浙江美保龙生物技术有限公司	一种df‑1细胞培养液添加剂及其制备方法、使用方法
EP3624851A1 (en)	2017-05-15	2020-03-25	Janssen Vaccines & Prevention B.V.	Stable virus-containing composition
CA3062549A1 (en)	2017-05-15	2018-11-22	Janssen Vaccines & Prevention B.V.	Stable virus-containing composition
WO2020033510A1 (en) *	2018-08-08	2020-02-13	Arizona Board Of Regents On Behalf Of Arizona State University	Method for improved poxvirus yields
EP3847246A1 (en)	2018-09-06	2021-07-14	Bavarian Nordic A/S	Storage improved poxvirus compositions
CA3152787A1 (en)	2019-09-02	2021-03-11	Arizona Board Of Regents On Behalf Of Arizona State University	Methods and compositions for improving oncolytic virus infection for nonpermissive cancers
JP7712284B2 (ja)	2020-03-12	2025-07-23	バヴァリアン・ノルディック・アクティーゼルスカブ	ポックスウイルスの安定性を改善する組成物
CN113355297A (zh) *	2021-06-23	2021-09-07	吉林冠界生物技术有限公司	一种灌流式培养全悬浮mdck细胞生产重组禽流感病毒的方法
JP2025524459A (ja)	2022-06-29	2025-07-30	バヴァリアン・ノルディック・アクティーゼルスカブ	エプスタイン・バー・ウイルスワクチン
IL317745A (en)	2022-06-29	2025-02-01	Bavarian Nordic As	Modified recombinant SARNA (VRP) and Vaccinia Ankara virus (MVA) prime regimen
CN116656628A (zh) *	2023-07-31	2023-08-29	深圳市卫光生物制品股份有限公司	一种痘病毒载体疫苗的制备方法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2004402A (en) *	1934-04-07	1935-06-11	Conklin John Edward	Atomizer
US3887430A (en)	1972-02-24	1975-06-03	Dow Chemical Co	Culture medium for tissue culture techniques
US4072565A (en)	1974-11-04	1978-02-07	The Dow Chemical Company	Production of viruses in tissue culture without use of serum
US3914408A (en)	1973-10-12	1975-10-21	Univ Nebraska	Vaccine for neonatal calf diarrhea
DE2714665A1 (de)	1977-04-01	1978-10-05	Mayr Anton	Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
US5833975A (en)	1989-03-08	1998-11-10	Virogenetics Corporation	Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5155020A (en)	1989-03-08	1992-10-13	Health Research Inc.	Recombinant poxvirus host range selection system
US5338683A (en)	1981-12-24	1994-08-16	Health Research Incorporated	Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
AU613583B2 (en)	1986-08-22	1991-08-08	Transgene S.A.	Proteins and the method for preparing them, DNA sequences, antibodies and their application, poxviruses, transformed or infected cells, pharmaceutical compositions which are useful in the prevention of schistosomiasis and application by way of an agent possessing glutathione s-transferase activity
US5024947A (en) *	1987-07-24	1991-06-18	Cetus Corporation	Serum free media for the growth on insect cells and expression of products thereby
CA1341245C (en) *	1988-01-12	2001-06-05	F. Hoffmann-La Roche Ag	Recombinant vaccinia virus mva
US6248333B1 (en)	1990-04-04	2001-06-19	Health Research Inc.	Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD)
AT393277B (de)	1990-01-04	1991-09-25	Immuno Ag	Verfahren zur herstellung von fruehsommer- meningoenzephalitis-virus (fsme-virus)-antigen
WO1992005246A1 (en) *	1990-09-25	1992-04-02	Smithkline Beecham Corporation	Medium for culture of mammalian cells
US5766598A (en)	1991-03-07	1998-06-16	Virogenetics Corporation	Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
US5843456A (en)	1991-03-07	1998-12-01	Virogenetics Corporation	Alvac poxvirus-rabies compositions and combination compositions and uses
EP0575491B1 (en)	1991-03-07	2003-08-13	Virogenetics Corporation	Genetically engineered vaccine strain
IL102929A (en)	1992-08-24	1996-11-14	Interpharm Lab Ltd	Serum-free medium for mammalian cells
US5403582A (en)	1993-01-21	1995-04-04	Nippon Zeon Co., Ltd.	Vaccine comprising fowlpox virus recombinants expressing the envelope glycoprotein of an avian reticuloendotheliosis retrovirus
US5405772A (en)	1993-06-18	1995-04-11	Amgen Inc.	Medium for long-term proliferation and development of cells
US5768598A (en)	1993-09-13	1998-06-16	Intel Corporation	Method and apparatus for sharing hardward resources in a computer system
US6015686A (en)	1993-09-15	2000-01-18	Chiron Viagene, Inc.	Eukaryotic layered vector initiation systems
US6190655B1 (en)	1993-12-03	2001-02-20	Immunex Corporation	Methods of using Flt-3 ligand for exogenous gene transfer
DE4405841C1 (de)	1994-02-23	1995-01-05	Mayr Anton Prof Dr Med Vet Dr	Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2243937T3 (es)	1994-04-29	2005-12-01	Baxter Healthcare S.A.	Poxvirus recombinados en regiones esenciales con la ayuda de polinucleotidos extraños.
US6146873A (en)	1994-11-10	2000-11-14	Baxter Aktiengesellschaft	Production of orthomyxoviruses in monkey kidney cells using protein-free media
US5753489A (en) *	1994-11-10	1998-05-19	Immuno Ag	Method for producing viruses and vaccines in serum-free culture
ATE542891T1 (de)	1994-11-10	2012-02-15	Baxter Healthcare Sa	Verfahren zur herstellung von biologischen produkten in protein-freier kultur
US5756341A (en) *	1994-11-10	1998-05-26	Immuno Ag	Method for controlling the infectivity of viruses
US5503582A (en)	1994-11-18	1996-04-02	Micron Display Technology, Inc.	Method for forming spacers for display devices employing reduced pressures
UA68327C2 (en)	1995-07-04	2004-08-16	Gsf Forschungszentrum Fur Unwe	A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
JPH09154571A (ja) *	1995-12-05	1997-06-17	Kurabo Ind Ltd	ウイルス製造用無血清培地
AP964A (en)	1996-02-21	2001-05-11	Julianna Lisziewicz	Methods and compositions for protective and therapeutic genetic immunisation.
WO1998004680A1 (en)	1996-07-26	1998-02-05	University Of Manitoba	Serum-free medium for growth of anchorage-dependant mammalian cells
ID19548A (id)	1996-09-24	1998-07-23	Bavarian Nordic Res Inst As	Virus mva rekombinan yang mengekspresikan antigen-antigen virus demam dan penggunaan daripadanya dalam vaksin-vaksin
US6103529A (en)	1996-10-10	2000-08-15	Life Technologies, Inc.	Animal cell culture media comprising peptides derived from rice
WO1998017283A1 (en)	1996-10-25	1998-04-30	The Wistar Institute Of Anatomy & Biology	Method of vaccinating infants against infections
US6204250B1 (en)	1996-11-22	2001-03-20	The Mount Sinai Medical Center Of The City Of New York	Immunization of infants
GB0023203D0 (en)	2000-09-21	2000-11-01	Isis Innovation	Vaccination method
US20030138454A1 (en)	1997-06-09	2003-07-24	Oxxon Pharmaccines, Ltd.	Vaccination method
GB9711957D0 (en)	1997-06-09	1997-08-06	Isis Innovation	Methods and reagents for vaccination
AT407255B (de)	1997-06-20	2001-02-26	Immuno Ag	Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
WO1999007869A1 (en)	1997-08-05	1999-02-18	University Of Florida	Live recombinant vaccine comprising inefficiently or non-replicating virus
US6605456B1 (en) *	1998-08-04	2003-08-12	Immunex Corporation	Nucleic acids encoding IKR-2, a protein kinase related to the I kappa B kinases
US6667176B1 (en) *	2000-01-11	2003-12-23	Geron Corporation	cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
ATE407206T1 (de)	1998-11-10	2008-09-15	Univ Rochester	Methoden zu herstellung von genbanken
EP2042598A1 (en)	1998-11-18	2009-04-01	Oxford Biomedica (UK) Limited	5T4 tumour-associated antigen for use in tumour immunotherapy
GB2370571B (en)	1998-11-18	2003-05-07	Oxford Biomedica Ltd	A modified 5t4 antigen
US6497883B1 (en)	1999-06-10	2002-12-24	Merial	Porcine circovirus recombinant poxvirus vaccine
DE19935351A1 (de)	1999-07-29	2001-02-01	Abb Daimler Benz Transp	Verfahren zur Energieoptimierung bei einem Fahrzeug/Zug mit arbeitspunktabhängigem Wirkungsgrad
KR100880765B1 (ko)	2000-03-14	2009-02-02	버베리안 노딕 에이/에스	변형된 백시니아 바이러스 안카라(ｍｖａ)의 변형 균주
JP2003533989A (ja)	2000-05-24	2003-11-18	メリアル	ブタ生殖・呼吸症候群ウィルス（ｐｒｒｓｖ）の組換えポックスウィルスワクチン
EP1303286B1 (de)	2000-07-11	2006-04-26	Bayer HealthCare AG	Verwendung von stämmen des parapoxvirus ovis zur herstellung von antiviralen arzneimitteln und arzneimitteln gegen krebs
ATE434035T1 (de) *	2000-09-25	2009-07-15	Polymun Scient Immunbio Forsch	Lebender influenza impfstoff und verfahren zu seiner herstellung
HU230198B1 (hu)	2000-11-23	2015-10-28	Bavarian Nordic A/S	Módosított Vacciniavírus Ankara-variáns
US7445924B2 (en) *	2000-11-23	2008-11-04	Bavarian Nordic A/S	Modified Vaccinia Ankara virus variant and cultivation method
US7097842B2 (en)	2000-11-23	2006-08-29	Bavarian Nordic A/S	Modified vaccinia virus ankara for the vaccination of neonates
UA82466C2 (uk) *	2001-07-18	2008-04-25	Бавариан Нордика А/С	Спосіб посилення ампліфікації хордопоксвірусу
EP1456230A2 (en)	2001-12-04	2004-09-15	Bavarian Nordic A/S	Flavivirus ns1 subunit vaccine
US6951752B2 (en)	2001-12-10	2005-10-04	Bexter Healthcare S.A.	Method for large scale production of virus antigen
US7094412B2 (en)	2001-12-10	2006-08-22	Bavarian Nordic A/S	Poxvirus containing formulations and process for preparing stable poxvirus containing compositions
US7056723B2 (en)	2001-12-20	2006-06-06	Bavarian Nordic A/S	Method for the recovery and purification of poxviruses from infected cells
FR2836924B1 (fr) *	2002-03-08	2005-01-14	Vivalis	Lignees de cellules aviaires utiles pour la production de substances d'interet
US7025970B2 (en)	2002-03-15	2006-04-11	Baxter International Inc.	Modified poxviruses, including modified smallpox virus vaccine based on recombinant drug-sensitive vaccinia virus, and new selection methods
ES2256747T3 (es)	2002-05-16	2006-07-16	Bavarian Nordic A/S	Expresion de genes en el virus de la vacuna modificado, usando el promotor ati de la viruela de la vaca.
UA82479C2 (uk)	2002-05-16	2008-04-25	Бавариан Нордика А/С	Міжгенні регіони як сайти вставки в геном модифікованого вірусу коров'ячої віспи ankara (mva)
AU2003264144C1 (en)	2002-09-05	2009-12-17	Bavarian Nordic A/S	Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
KR101121971B1 (ko) *	2003-07-22	2012-03-09	비바리스	부착성 또는 비부착성 조류 세포주를 이용한폭스바이러스의 생산
US6915752B2 (en) *	2003-09-30	2005-07-12	Lockheed Martin Corporation	Utility service protection strip
US6976752B2 (en)	2003-10-28	2005-12-20	Lexmark International, Inc.	Ink jet printer with resistance compensation circuit

2003
- 2003-09-01 AU AU2003264144A patent/AU2003264144C1/en not_active Expired
- 2003-09-01 MX MXPA04012966A patent/MXPA04012966A/es active IP Right Grant
- 2003-09-01 JP JP2004533438A patent/JP2005537793A/ja active Pending
- 2003-09-01 WO PCT/EP2003/009704 patent/WO2004022729A1/en not_active Ceased
- 2003-09-01 BR BRPI0313559A patent/BRPI0313559B8/pt active IP Right Grant
- 2003-09-01 DK DK03766057.8T patent/DK1434858T4/en active
- 2003-09-01 UA UAA200502041A patent/UA85543C2/ru unknown
- 2003-09-01 DE DE60320520.8T patent/DE60320520T3/de not_active Expired - Lifetime
- 2003-09-01 HK HK06100219.9A patent/HK1080507B/zh not_active IP Right Cessation
- 2003-09-01 CA CA2494379A patent/CA2494379C/en not_active Expired - Lifetime
- 2003-09-01 AT AT03766057T patent/ATE393212T2/de active
- 2003-09-01 ES ES03766057T patent/ES2305514T5/es not_active Expired - Lifetime
- 2003-09-01 PL PL373992A patent/PL215169B1/pl unknown
- 2003-09-01 CN CN038188694A patent/CN1692156B/zh not_active Expired - Lifetime
- 2003-09-01 NZ NZ538575A patent/NZ538575A/en not_active IP Right Cessation
- 2003-09-01 PT PT03766057T patent/PT1434858E/pt unknown
- 2003-09-01 SI SI200331281T patent/SI1434858T2/sl unknown
- 2003-09-01 EP EP03766057.8A patent/EP1434858B2/en not_active Expired - Lifetime
- 2003-09-01 EA EA200500448A patent/EA009008B1/ru not_active IP Right Cessation
- 2003-09-01 KR KR1020057000155A patent/KR101044538B1/ko not_active Expired - Lifetime
2005
- 2005-03-03 US US11/071,814 patent/US7695939B2/en not_active Expired - Lifetime
- 2005-03-04 NO NO20051175A patent/NO343489B1/no not_active IP Right Cessation
2008
- 2008-07-23 CY CY20081100766T patent/CY1114598T1/el unknown
- 2008-10-01 US US12/243,332 patent/US7964397B2/en not_active Expired - Fee Related
2010
- 2010-03-12 JP JP2010055602A patent/JP5612338B2/ja not_active Expired - Lifetime
2011
- 2011-05-12 US US13/106,026 patent/US8329466B2/en not_active Expired - Fee Related
2012
- 2012-11-29 US US13/688,473 patent/US8673318B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EA200500448A1 (ru)	2005-08-25
EP1434858B1 (en)	2008-04-23
BRPI0313559B1 (pt)	2019-02-26
NO20051175L (no)	2005-03-04
DE60320520T2 (de)	2008-12-11
ES2305514T5 (es)	2019-06-14
DK1434858T4 (en)	2019-04-01
JP2010148522A (ja)	2010-07-08
JP2005537793A (ja)	2005-12-15
US20110217749A1 (en)	2011-09-08
DK1434858T3 (da)	2008-08-11
ES2305514T3 (es)	2008-11-01
KR101044538B1 (ko)	2011-06-27
CN1692156B (zh)	2011-05-11
WO2004022729A8 (en)	2005-03-17
BR0313559A (pt)	2005-07-12
HK1080507A1 (en)	2006-04-28
EA009008B1 (ru)	2007-10-26
US20130089913A1 (en)	2013-04-11
AU2003264144C1 (en)	2009-12-17
MXPA04012966A (es)	2005-05-16
NZ538575A (en)	2007-03-30
NO343489B1 (no)	2019-03-25
US8673318B2 (en)	2014-03-18
SI1434858T2 (sl)	2019-05-31
CN1692156A (zh)	2005-11-02
PT1434858E (pt)	2008-07-28
HK1080507B (zh)	2011-10-07
ATE393212T2 (de)	2008-05-15
DE60320520T3 (de)	2019-05-09
PL215169B1 (pl)	2013-10-31
BRPI0313559B8 (pt)	2021-05-25
SI1434858T1 (sl)	2008-10-31
US7695939B2 (en)	2010-04-13
CA2494379C (en)	2012-11-06
US8329466B2 (en)	2012-12-11
UA85543C2 (ru)	2009-02-10
EP1434858B2 (en)	2018-12-19
AU2003264144B2 (en)	2009-05-14
WO2004022729A1 (en)	2004-03-18
KR20050037551A (ko)	2005-04-22
EP1434858A1 (en)	2004-07-07
US20090029459A1 (en)	2009-01-29
CY1114598T1 (el)	2016-10-05
AU2003264144A1 (en)	2004-03-29
CA2494379A1 (en)	2004-03-18
AU2003264144A2 (en)	2004-03-29
DE60320520D1 (de)	2008-06-05
US20050214324A1 (en)	2005-09-29
US7964397B2 (en)	2011-06-21
JP5612338B2 (ja)	2014-10-22

Publication	Publication Date	Title
SI1434858T2 (sl)	2019-05-31	Postopek za pomnoževanje poksvirusa v razmerah brez seruma
ES2526191T3 (es)	2015-01-08	Método para producir virus influenza B infeccioso en cultivo celular
IL250313B (en)	2019-06-30	Expansion of renewable stem cell populations
DK0904351T3 (da)	2010-11-01	Dyreceller og fremgangsmåder til replikationen af influenzavirus
NO20054124L (no)	2005-09-27	Dyre-fri celle kultur metode
PL1646715T3 (pl)	2010-10-29	Wytwarzanie pokswirusów za pomocą linii adherentnych lub nieadherentnych komórek ptasich
EA200200604A1 (ru)	2002-12-26	Производство вакцин
WO2004090140A3 (en)	2004-12-23	Methods and means for increasing the tolerance of plants to stress conditions
HUP0000992A2 (hu)	2000-11-28	Sejttenyészetben szaporodni képes, géntechnológiailag módosított, fertőző nyálkatömlő-betegséget okozó vírus (IBDV) mutánsai
CA2437962A1 (en)	2002-09-26	Method of extracting virus from cell culture
HUP0002903A2 (hu)	2000-12-28	Növénytranszformációs módszerek
CY1111775T1 (el)	2015-10-07	Πνευμονικα κυτταρα βαμβακοαρουραιου για καλλιεργεια ιου
WO2001083710A3 (en)	2002-05-02	Clearance of neoplastic cells from mixed cellular compositions using viruses
WO2003049767A3 (en)	2004-03-11	Method of large scale production of hepatitis a virus
DE69824856D1 (de)	2004-08-05	Rückgewinnung von viren aus zellkulturen durch verwendung einer hypertonischen salzlösung
DE60106222D1 (de)	2004-11-11	Herpesviren für die modulation einer immunantwort
AU2003257485A1 (en)	2004-02-09	Method for the production of transgenic plants with increased virus resistance by silencing vegetable dnaj-like proteins
HUP9800113A2 (hu)	1998-09-28	Transzgenikus vírus
EP4357447A3 (en)	2024-07-10	Serum-free medium for avian vaccine production and uses thereof
WO2002028174A1 (en)	2002-04-11	Methods of infection with hepatitis c virus
ATE486124T1 (de)	2010-11-15	Keratinozyten-kulturverfahren und verwendung davon
DK1238057T3 (da)	2006-05-08	Fremgangsmåde til produktion af vedhæftende dyreceller
DE60319210D1 (de)	2008-04-03	Verfahren zur virusproduktion
CA2250714A1 (en)	1997-10-09	Animal cells and processes for the replication of influenza viruses
WO2008078056A3 (fr)	2008-10-02	Procédé d'amplification du vhc chez les aedes mosquitoes